{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SGLT2i",
    "query": {
      "intervention": "SGLT2i"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 70,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SGLT2i&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T05:29:02.613Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06143566",
      "title": "Polypill for Prevention of Cardiomyopathy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "High Blood Pressure"
      ],
      "interventions": [
        {
          "name": "Polypill",
          "type": "DRUG"
        },
        {
          "name": "Combined prescription of the individual medications",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 200,
      "start_date": "2024-03-11",
      "completion_date": "2027-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-09-02T05:29:02.613Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06143566"
    },
    {
      "nct_id": "NCT05214573",
      "title": "Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Type 2 Diabetes",
        "Cardiac Disease"
      ],
      "interventions": [
        {
          "name": "Glucagon like peptide 1 receptor agonist",
          "type": "DRUG"
        },
        {
          "name": "Sodium-glucose cotransporter 2 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Dipeptidyl Peptidase 4 Inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Sulfonylurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 386301,
      "start_date": "2021-12-01",
      "completion_date": "2025-07-22",
      "has_results": true,
      "last_update_posted_date": "2025-10-10",
      "last_synced_at": "2026-09-02T05:29:02.613Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05214573"
    },
    {
      "nct_id": "NCT06142006",
      "title": "The Diabetes Staging System in Patient Aligned Care Teams",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus",
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Diabetes Staging System (DSS) use among Primary Care Teams",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Durham VA Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "25 Years to 75 Years"
      },
      "enrollment_count": 120,
      "start_date": "2023-09-01",
      "completion_date": "2025-09-01",
      "has_results": false,
      "last_update_posted_date": "2024-04-15",
      "last_synced_at": "2026-09-02T05:29:02.613Z",
      "location_count": 1,
      "location_summary": "Greenville, North Carolina",
      "locations": [
        {
          "city": "Greenville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06142006"
    },
    {
      "nct_id": "NCT07060417",
      "title": "Vascular Effects of SGLT2i in Non-diabetic CKD",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-diabetic Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2026-10-01",
      "completion_date": "2029-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-09-02T05:29:02.613Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07060417"
    },
    {
      "nct_id": "NCT05138575",
      "title": "SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure With Preserved Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "Empagliflozin + Potassium Chloride",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin + Potassium Nitrate",
          "type": "DRUG"
        },
        {
          "name": "Potassium Chloride + Placebo for Empagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2022-01-24",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-09-02T05:29:02.613Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05138575"
    },
    {
      "nct_id": "NCT06150924",
      "title": "Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD",
          "type": "DRUG"
        },
        {
          "name": "Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mineralys Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2023-12-14",
      "completion_date": "2025-04-23",
      "has_results": true,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-09-02T05:29:02.613Z",
      "location_count": 44,
      "location_summary": "Glendale, Arizona • Phoenix, Arizona • Chula Vista, California + 39 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "El Centro",
          "state": "California"
        },
        {
          "city": "Granada Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06150924"
    },
    {
      "nct_id": "NCT07053306",
      "title": "SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Empagliflozin 25 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 29,
      "start_date": "2025-04-29",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-09-02T05:29:02.613Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07053306"
    },
    {
      "nct_id": "NCT06674109",
      "title": "SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Gout and Hyperuricemia"
      ],
      "interventions": [
        {
          "name": "Empagliflozin 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 60,
      "start_date": "2026-07-01",
      "completion_date": "2028-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-08-05",
      "last_synced_at": "2026-09-02T05:29:02.613Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06674109"
    },
    {
      "nct_id": "NCT07053319",
      "title": "SGLT2i, Pioglitazone, and Ketone Production in T2D",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Empagliflozin 25 MG",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 64,
      "start_date": "2026-05-11",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-09-02T05:29:02.613Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07053319"
    },
    {
      "nct_id": "NCT07211802",
      "title": "CKM For Safe Use of SGLT2i in Type 1 Diabetes",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes (T1D)"
      ],
      "interventions": [
        {
          "name": "Sotagliflozin Low Dose",
          "type": "DRUG"
        },
        {
          "name": "Sotagliflozin High Dose",
          "type": "DRUG"
        },
        {
          "name": "Dual Continuous Glucose and Ketone Monitor",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2026-07-01",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-10-08",
      "last_synced_at": "2026-09-02T05:29:02.613Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07211802"
    }
  ]
}